The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of androgen deprivation (AD) +/- cixutumumab, in new metastatic hormone-sensitive prostate cancer (mHSPC).
 
Risa Liang Wong
No Relationships to Disclose
 
Mai T. Duong
No Relationships to Disclose
 
Catherine Tangen
No Relationships to Disclose
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Foundation One Inc; Lilly; Lilly; Medivation/Astellas; Nektar; Pfizer; Pharmacyclics
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Heather H. Cheng
Research Funding - Astellas Medivation (Inst); Clovis Oncology (Inst); Color Genomics Foundation (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Sanofi (Inst)
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Novartis; Pfizer; UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Caris Life Sciences; Clovis Oncology; Corvus Pharmaceuticals; Eisai; Genentech/Roche; Janssen Oncology; Merck; Modra Pharmaceuticals; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Genentech/Roche; Sanofi
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; Sanofi/Aventis; US Oncology
 
Maha H. A. Hussain
Honoraria - Astellas Pharma; Astellas Pharma; Genentech; Genzyme; MLI PeerView; Onclive; PER; PER; Phillips Gilmore Oncology; projects in Knowledge; Research to Practice; Sanofi; Sanofi
Consulting or Advisory Role - AstraZeneca; Bayer; Pfizer
Research Funding - AstraZeneca (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Genentech; Genentech/Roche; Pfizer; Sanofi
 
Ian Murchie Thompson
Consulting or Advisory Role - Magforce; Profound Medical; Rapamycin Holdings
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Mundipharma; Novartis; Pfizer; Pharmacyclics; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; Seagen; US Biotest
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Bristol-Myers Squibb Japan; Exelixis; Merck; Roche
(OPTIONAL) Uncompensated Relationships - Eisai; US Biotest
 
Evan Y. Yu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Incyte; Janssen; Merck; Pharmacyclics; QED Therapeutics; Seagen
Research Funding - Daiichi Sankyo (Inst); Dendreon (Inst); Merck (Inst); Seagen (Inst); Taicho (Inst)